Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors: DEEPER

Next Previous
Trial Profile

A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors: DEEPER

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Bevacizumab; Fluorouracil; Irinotecan; Levofolinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms DEEPER

Most Recent Events

  • 20 Jan 2024 Results(n=137) investigating the association between GWMS and clinical outcomes of first-line chemotherapy with anti-EGFR or anti-VEGF antibody agents for metastatic colorectal cancer, presented at the 2024 Gastrointestinal Cancers Symposium
  • 24 Oct 2023 Results of an updated survival analysis performed using BRAF status added by tumor tissue biomarker analysis presented at the 48th European Society for Medical Oncology Congress
  • 16 Oct 2023 According to a Merck & Co media release, data of this study will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top